Modality
mRNA
MOA
CDK4/6i
Target
PLK4
Pathway
Autophagy
Melanoma
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
~Jan 2017
→ ~Apr 2018
Phase 3
~Jul 2018
→ ~Oct 2019
NDA/BLA
Jan 2020
NDA/BLACurrent
NCT06203371
371 pts·Melanoma
2020-01→TBD·Not yet recruiting
371 total pts1 indication
Approved
CompletedCurrentUpcoming
Trial Timeline
2020
NDA/BLA
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06203371 | NDA/BLA | Melanoma | Not yet recr... | 371 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| NBI-3153 | Neurocrine | Approved | Aβ |